Save up -80% on Pertuzumab
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Perjeta
|$4,970.83||1 vial 420mg/14ml|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Pertuzumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Pertuzumab every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Pertuzumab volume of distribution
In the previously developed model, pertuzumab PK were described by a two-compartment linear model with a CL, central volume of distribution, and terminal elimination half-life of 0.235 L/day, 3.11 L, and 18 days, respectively. The covariates identified as significantly influencing pertuzumab CL were baseline serum albumin and LBW, with 15.5% and 4.1% of the between-subject variability in CL explained by serum albumin and LBW, respectively.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Pertuzumab
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
Pertuzumab mechanism of action
Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and HER4) on the surface of cancer cells. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and previous clinical trials of pertuzumab in a single agent setting had suggested clinical activity – including stable disease – in heavily pretreated patients with advanced ovarian and breast cancers.
Dosage forms of Pertuzumab
|Perjeta||14ml||2 vials 420mg||$9,934|
2C4 Antibody MOAB 2C4
Hoffmann La Roche Limited
Humans and other mammals
Indication of Pertuzumab
Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Toxicity of Pertuzumab
The most common adverse reactions ( 30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Pertuzumab on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.